logologo
QuantliQuantli

AquaBounty Technologies Inc

AQB

NASDAQ

Biotechnology

$1.49

USD

-0.02 (-1.00%)

At close: Aug 14, 2026, 4:00 PM EDT

Market Cap $7.21M

Volume 273.3K

Price (USD)
Price (USD)

About AquaBounty Technologies Inc

AquaBounty Technologies, Inc. engages in the provision of land-based aquaculture services. The company is headquartered in Harvard, Massachusetts and currently employs 3 full-time employees. The company went IPO on 2017-01-09. The Company’s technology advances in fish breeding, genetics, and health and nutrition. The company locates its land-based recirculating aquaculture system farms close to key consumption markets, which are designed to prevent disease and to include multiple levels of fish containment to protect wild fish populations. Its land-based farms utilize Recirculating Aquaculture Systems, which are designed to prevent disease and include multiple levels of fish containment designed to protect wild fish populations. Recirculating Aquaculture Systems facilities provide water treatment technology, including the use of ozone, salt treatment and ultraviolet radiation to kill potential bacterial, fungal, or viral pathogens which might enter the system.

CEO

Mr. David Frank

HQ

Harvard, MASSACHUSETTS, US

Founded

2017

Employees

3

Key Metrics

2 metrics our research team weighs before forming a view on AQB.

Based on Quantli research · SEC filings · as of Q2 2026

METRIC

VALUE

CHANGE

TREND (3Y)

ROE (TTM)

-652.7%

+12.0 pp

Free Cash Flow (TTM)

$-7.18M

Financial Snapshot

Full Financials

Revenue

$0

YoY

Gross Margin

YoY

Net Income

$-18.35M

+79.7%

YoY

Operating Cash Flow

$-7.18M

+20.6%

YoY

Key Statistics

Open

$1.47

Previous Close

$1.50

Day Range

$1.45 - $1.62

52 Week Range

$0.70 - $2.95

Volume

273.3K

Average Volume (10 Days)

2.9M

Dividend Yield

Valuation Measurement

Market Cap

$7.21M

P/E Ratio (TTM)

Price / Book

2.56

Financial Highlights

Return on Assets

-156.7%

Return on Equity

-652.7%

Revenue (TTM)

$0

Net Income (TTM)

$-18.35M

Diluted EPS (TTM)

-$4.59

Total Cash (MRQ)

$1.89M

Levered FCF (TTM)

$-7.18M

Turn research into action

Knowing a stock is strong is the start. Knowing how to invest in it when you spot good research is good returns.

Swing Strategy

Buy support, sell on recovery.

Best for:

Risk-tolerant

Trend Following

Enter on trend. Cut losses fast.

Best for:

Active traders

Position Strategy

Ride market cycles. Patient hold.

Best for:

Patient investors

Go deeper on AQB

Similar Stocks

ENSC

Ensysce Biosciences Inc

$0.4000

+14.8%

ERNA

Ernexa Therapeutics Inc

$4.27

-0.7%

CELZ

Creative Medical Technology Holdings Inc

$1.22

-1.6%

AKTX

Akari Therapeutics PLC

$7.54

+7.7%

FBLG

Fibrobiologics Inc

$1.06

-7.8%

ALZN

Alzamend Neuro Inc

$1.55

+6.2%

Earnings Calendar

Next Earnings

Estimated Q3 Release

Oct 26